secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0001651308-23-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene Q4 product revenue $339M (+72% YoY); BRUKINSA sales $176M (+101%); tislelizumab gets 10th China approval
--------------------------------------------------------------------------------

- Product revenue $339M Q4, $1.3B FY2022, up 72% and 98% YoY; net loss $445M Q4, $2.0B FY.
- BRUKINSA global sales $176M Q4 (+101%), $565M FY (+159%); U.S. sales $125M Q4 (+124%).
- Tislelizumab China sales $102M Q4 (+88%), $423M FY (+66%); NMPA approved 10th indication for first-line gastric cancer.
- Cash $4.5B at Dec 31, 2022; operating cash burn $1.5B FY.
- BRUKINSA received U.S. FDA approval for CLL/SLL in Jan 2023; EC approval for CLL.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000031/0001651308-23-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000031/bgne-20230224.htm
  HTML page:      https://secwatch.observer/filing/0001651308-23-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer